The Armauer Hansen Research Institute (AHRI) was founded in 1970 through the initiative of the Norwegian and Swedish Save the Children organizations seconded by the Ministry of Health of Ethiopia. The Institute got its name from the Norwegian physician, Gerhard Henrik Armauer Hansen, who first described the leprosy bacillus (Mycobacterium leprae). AHRI is a biomedical research institute that works in developing tools for prevention, control and treatment of mycobacterium and other diseases of public healthy importance through applied and basic biomedical research and training.
In collaboration with Karolinska Institute, Stockholm, Sweden, Addis Ababa University College of health science, All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre (ALERT) and Tikur Anbasa Specialized Hospital, Addis Ababa, Ethiopia; Armauer Hansen Research Institute (AHRI) is conducting a study on Exploring epigenetic alterations of cellular immunity in multidrug-resistant tuberculosis with relevance for new therapy using epigenetic- and immune-modulating drugs. The project aims to reach beyond conventional chemotherapy by exploring therapeutic strategies that could enhance the ability of the immune system to effectively eradicate Mtb infection.
Main Role & Responsibilities: